ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture - Pharmaceutical Technology

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge. As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge. Novartis hopes to leverage fast CAR-T production through its T-Charge platform to position LB2102 against Amgen’s leader Imdelltra. Credit: Kateryna Kon/Shutterstock.com Legend Biotech presented preliminary results from its ongoing Phase I/II trial of LB2102 (NCT05680922), an armoured delta-like ligand 3 (DLL3)-targeted autologous chimeric antigen receptor (CAR)-T cell therapy, in patients with relapsed or refractory (r/r) small cell lung cancer (SCLC)…

Source: Pharmaceutical Technology